Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic Loss of Exclusivity
The biggest mistake in biologics business development isn’t pricing—it’s timing.
In the sterile manufacturing world, the “…
Generic competition isn’t just a legal event—it’s a business strategy.
For years, the public narrative around drug patents has been simple: a patent expires, generics arrive, prices fall. But the reality is more nuanced—and often more aggressive. In …
Patients aren’t asking “about patents.” They’re asking: “Will this work for me?”
If you’ve spent any time reading what people search online, you’ll notice a pattern: the questions rarely start with legal language. They start with lived experience—side …
Drug Switching Questions: What Patients Are Really Asking Online Read Post »
Brand teams don’t lose to competitors—they lose to time. And time, in pharma, is often stolen quietly through “evergreening”: incremental formulation tweaks, new delivery mechanisms, method-of-use claims, and patent thickets that turn a clear path to g…
GPT, Rosalind, and the Generic Drug Question: What OpenAI’s Life Sciences Model Actually Changes
The life sciences industry has a habit of treating “AI” like a monolith—either it’s magic, or it’s hype. But the real story is more interesting: the shift …
GPT-Rosalind and Generic Drugs: What OpenAI’s Life Sciences Model Actually Changes Read Post »
The Patent Cliff Isn’t Coming—It’s Already Here.
If you work in pharma strategy, you’ve heard the phrase “patent cliff” so often it can start to sound abstract. But the reality is brutally concrete: once exclusivity ends, revenue doesn’t just decline…
Beat the Patent Cliff: How to Trigger Payer Strategy Campaigns Before Drug Patent LOE Read Post »
ð¨ The next “AI breakthrough” in pharma may not be a new molecule—it may be a faster way to win the patent war.
OpenAI’s GPT and Rosalind have reportedly “smashed drug patent cliffs,” delivering results that are 70% faster in key analysis workflows. …
OpenAI’s GPT-Rosalind = Smashed Drug Patent Cliffs and 70% Faster ANDAs Read Post »
Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
In pharma, the most expensive surprises rarely arrive with a press release. They arrive quietly—months before launch—inside a filing window that competitors …
Your drug patent doesn’t “last” the same way everywhere. In the GCC, the clock can start, pause, or effectively run differently—depending on how you file, what you claim, and where you launch.
If you’re a pharma leader, brand team, or investor, you alr…
Know Exactly How Long Your Drug Patent Lasts in the GCC Read Post »
Unlocking the Hidden Timeline: How Long Do Drug Patents Last in the GCC?
Imagine investing millions into developing a groundbreaking medication, only to find out that your exclusive rights could expire sooner than expected, or worse, that your competit…
Know Exactly How Long Your Drug Patent Lasts in the GCC Read Post »
Get new actionable insights and updates from BiotechBlog
